These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Progress in Understanding What Is Being Statin(ed) in Prostate Cancer. Ramos JD; Yu EY JAMA Oncol; 2015 Jul; 1(4):428-30. PubMed ID: 26181247 [No Abstract] [Full Text] [Related]
3. Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer. Harshman LC; Wang X; Nakabayashi M; Xie W; Valenca L; Werner L; Yu Y; Kantoff AM; Sweeney CJ; Mucci LA; Pomerantz M; Lee GS; Kantoff PW JAMA Oncol; 2015 Jul; 1(4):495-504. PubMed ID: 26181260 [TBL] [Abstract][Full Text] [Related]
4. Primary androgen deprivation therapy in men with prostate cancer. Laufman L JAMA; 2009 Jan; 301(1):35; author reply 35. PubMed ID: 19126809 [No Abstract] [Full Text] [Related]
5. Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist. Boudreaux KJ; Chang SS BJU Int; 2008 Mar; 101(6):671-4. PubMed ID: 18070172 [No Abstract] [Full Text] [Related]
6. Measuring the effectiveness of androgen-deprivation therapy for prostate cancer in the medicare population: adequate data are neither the same as nor the enemy of perfect data. Trinh QD; Schrag D JAMA Intern Med; 2014 Sep; 174(9):1468-9. PubMed ID: 25023522 [No Abstract] [Full Text] [Related]
11. Hormone-refractory prostate cancer: what have we learned? Wirth MP BJU Int; 2007 Jul; 100 Suppl 2():56-9. PubMed ID: 17594362 [No Abstract] [Full Text] [Related]
12. [Hormone refractory prostate cancer and the prevention of the adverse effects of the treatment]. Zgliczyński S; Borówka A Endokrynol Pol; 2005; 56(3):223. PubMed ID: 16350713 [No Abstract] [Full Text] [Related]
13. [Basic and clinical characteristics of flutamide]. Suzuki K; Nakazato H; Kurokawa K; Yamanaka H Nihon Rinsho; 2000 Jul; 58 Suppl():211-5. PubMed ID: 11022716 [No Abstract] [Full Text] [Related]
15. Androgen deprivation and antagonism in the treatment of advanced prostatic carcinoma. Gibbs SJ; Plowman PN Clin Oncol (R Coll Radiol); 1996; 8(6):346-52. PubMed ID: 8973848 [No Abstract] [Full Text] [Related]
16. Medicare reimbursement and prescribing hormone therapy for prostate cancer. Keating NL J Natl Cancer Inst; 2010 Dec; 102(24):1814-5. PubMed ID: 21131579 [No Abstract] [Full Text] [Related]
17. The role of hormonal treatment in prostate cancer. Flüchter SH; Weiser R; Gamper C Recent Results Cancer Res; 2007; 175():211-37. PubMed ID: 17432562 [TBL] [Abstract][Full Text] [Related]
18. Intermittent androgen suppression. Too good to be true? Abrahamsson PA Scand J Urol Nephrol Suppl; 1999; 203():45-9. PubMed ID: 10636570 [TBL] [Abstract][Full Text] [Related]
19. Bicalutamide (Casodex): The Critical Issues 1996. Proceedings of a meeting. Boston, Massachusetts, July 6-9, 1995. Urology; 1996 Jan; 47(1A Suppl):1-96. PubMed ID: 8560672 [No Abstract] [Full Text] [Related]
20. [Somatostatin analogs in the combined treatment of patients with hormone-resistant prostate cancer]. Kaprin AD; Gafanov PA; Fastovets SV Vopr Onkol; 2009; 55(4):474-6. PubMed ID: 19947374 [No Abstract] [Full Text] [Related] [Next] [New Search]